RDB07877 - pGL3-AID R4 mut. NF-kB-2

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pGL3-AID R4 mut. NF-kB-2 (#RDB07877)

Reporter construct of mouse Aicda locus

Clone info.	Reporter construct of mouse Aicda locus with firefly luciferase. Cloned position, -9226 to -7585.
Comment	Nat. Immunol. (2010) 2, 148-154, Fig. 4c.
Vector backbone	pGL3 (Plasmid)
Selectable markers	Amp^r
Gene/insert name	Mouse Aicda genomic DNA
Depositor\|Developer	Honjo, Tasuku \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] MTA, for use for for-profit purpose [Word] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 提供同意書 (MTA, 営利目的用)[Word] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

必要書類

提供依頼書

[依頼書の記入例

]
提供同意書 (MTA, 非営利学術目的用)[Word

] [MTAの記入例

]
提供同意書 (MTA, 営利目的用)[Word

]
手続きの概要は、「提供申込みについて[link]」をご覧ください。

MTAに書く使用条件

利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。
MTAに書く付加的使用条件：
本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07877	pGL3-AID R4 mut. NF-kB-2	DNA solution	JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pGL3-AID R4 mut. NF-kB-2 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07877).

Reference section:

Tran, T.H., Nakata, M., Suzuki, K., Begum, N.A., Shinkura, R., Fagarasan, S., Honjo, T., Nagaoka, H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB07877_A4Gi.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: pGL4-4174F Sequence file: RDB07877_A4Gia.seq
>07877_07877_A4Gi_pGL4-4174F_A05_02.ab1 1 GTTCGGGTCC AGGACATTTC TCTATCGATA GGTACCCACC ACTCTCGGCT GTTCTGGAAC 61 TCTCTGTAAC CTCGGGCTGT ATGAGTGTAT GTGAGTGTGT GTATATGGGT GTGGGGGGGG //
Primer: Luc_R Sequence file: RDB07877_A4Gib.seq
>07877_07877_A4Gi_Luc_R_B05_05.ab1 1 CTTTGGCTTC CAGGAACAGG GCGTATCTCT TCATAGCCTT ATGCAGTTGC TCTCCAGCGG 61 TTCCATCTTC CAGCGGATAG AATGGCGCCG GGCCTTTCTT TATGTTTTTG GCGTCTTCCA 121 TGGATCGGTC TCCAGCGTGA CTTTCTTGAC TCCCTCAAAG TCTTAGGCCA AAGGAAGCTT 181 GCTTCAAGCA AGGCTGCTTC AGTGCTGTTG TGTGACAGAG CACTGGCCCC TGGCATTCAA 241 ATCTGAGCTT GCTCTTGTGG GCTCCTCCCC CACGACAGCA TCACTACCAC CAGGTATCCA 301 ACATCTGCCT CCTGGGTTGG GTCCAGTAAA GATGGGCGGG GCTGTGGTGG GCAAAGCCAC 361 ACGGATTAAA TGATTGGGGG GGGGGGCCAG TTCTGCTCAT GCTTAATGTC CAACTTCCTT 421 CGAGGCTGTT CCTCTAAACT CGAGCTGTAG CACACGCACA CGCACGCCCA CACCCTCTCT 481 TACAGATGCC GTACACATGC CATAGGAACA AATACAAAAC CCTTGATTTG TAAGAAAGCC 541 AAATTCTCTC ATTTGCCTTC TTCTAAAGGA AGGAAAGAGA TCTCACTTAG TTACAAAAAC 601 CATTTTCCAG TCCCGGGAAA TTTGGAACTG GTACAGCGGC AAAGCAGTTT ACAGGGTTTT 661 GATCAACTTT TATTTTCTTC ATTAACTTCT CTTTCCCCTC ATTAACTTCT ATTGAAAAAC 721 CACAAGCCAA CTTGGTCACA TTGTTTTTAA CCAAAAATAC TGTGACTTGG AAATCGAGTC 781 GCCTGCGGCT GAGCTGAGTT TTGGACATCT GGAGTTCACC ACCTCGCTTT CCCTATGAGA 841 CACACAGGTG AGGTTTCGTT ATGGCCAGCA TGAGGGGCTG GCGGTCTCTG GAAAGCCTCG 901 GGGGGGGGGG GGGGGGGGCT GCATTCCTGT GTCTCAAAGC CAGCACACTC AGAACATGAA 961 CTCCCTCGGG GTCACTATTT TTTTGGACAC CAGCTAAGAT TGCTCAATAT GATACTGGGT 1021 TTGTTTTTAA GGGAATCCAA AAAGGCTTTT GTGTGGGTGA AAAATGTGTG ATGGATGCTC 1081 CAACTTCTGC ATCCCGATTT TGATTTTCTC CACTTGGTGG ACCCTGA //
Primer: R4-M_R Sequence file: RDB07877_A4Gic.seq
>07877_07877_A4Gi_R4-M_R_F05_17.ab1 1 AAGATCGATT TGTTTTTCTC ACTTTGTGGC CCTGGAGGTT ACTGCATCCC TCTGGGGTAT 61 GAAAAGCCAT GATACAGTGC TCAGACACAG ACCAGAATTA CTCAGCTTCT GCTGTTGGGC 121 TGCCCAGGAC ATTTCAAAGA CCAGAGAACT GTAAACAGGT ATTTATCAAA AGCTTAGGTC 181 TACGGGGAGG TGGAGGCAGG AGGATTGAGA GTTCAAGGCC ATCTTCTGCC TCGTGTTGAA 241 TTCAAGGCCA GCAGGCAGGT TTGAAAGAAA AAAAGAATTT TCAAATGGAA TACTATGAAA 301 TTAAAAGGCT TCAAACTGAG TGTGGTGACT AATCCTAGCA GCCTGGAGGT TGAGGCAGGA 361 GGATTGTCAA GAGTTGGAAA CCACCTTGAG CTCCATCCCA GGACCCACAT GGTAGGGGGA 421 GTGAACCAAT TCATGCAAGT TGTCCACTGA CCTCTACGCT CATACACACA CACACTCATA 481 CACACACCCA TAATACACAC TCACACACAC TCATACACAC ACCCATACAC ACACTCATAC 541 ACACACACAC CCACACACAC ACCCATACAT ACACACTCAC ATATACTCAT ACACCCTCAT 601 CCCCACACCC ATATACACAC ACTCACACAC ACTCATACAC ACACTCATAC ACACACACCT 661 CACACCCATA CATACACACT CACATACACT CATATACCCT CACCCCCCCA TATACACACA 721 CTCACACACA CTCATACACA CACTCATACA CACACTCATA CACACACACA CCTCACACCC 781 ATACATACAC ACTCACATAC ACTCATATAC TCTCACCCCC CCCCACACCC ATATACACAC 841 ACTCACATAC ACTCATACAG CCCGAGGTTA CAGAGAGTTC CAGAACAGCC GAGAGTGGTG 901 GGTACCTATC GATAGAGAAA TGTTCTGGCA CCTGCACTTG CACTGGGGAC AGCCTATTTT 961 GCTAGTTTGT TTTGTTTCGT TTTGTTTTGA TGGAGAGCGT ATGTTAGTAC TATCGATTTC 1021 ACACAAAAAA ACCCAACACA CAGATGGTAT GAAAATAAGA TATTTTAATG GCCGCGGCTC 1081 TAGTACCTCC CGTAGTTAGT ATACTACTAT CATGCTAGCC TTGAGCTGGG GGCGGCTATA 1141 G //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original	Tran, T.H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806. [link to RRC of NBRP]

Resource search

Link

Other resources in our bank

mouse Aicda

External Database
Mouse Aicda

Reference sequence